Research issues affecting preoperative systemic therapy for operable breast cancer.
about
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerKi67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model.Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.Pharmacotherapy of triple-negative breast cancer.Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
P2860
Q30460977-8FE3F5BD-D433-4A64-B8DC-F13A76AFA40CQ33922971-0CD0003B-1FFB-4571-8648-44C6294EF19EQ33984087-83F968D5-66C4-4368-85F8-4D09AB9BC7C1Q33996547-781C6494-E8E4-42D2-8C17-73C4223E1582Q34050338-AEE2EE74-172C-4353-870C-FAA86C3178EDQ34074868-D5A6ADF4-D555-497D-A189-BBC2B7F3E258Q34948192-070E9298-7237-48C1-A76F-E51366C10437Q35155635-83E46915-C47C-4993-B2D3-12950102589EQ35252217-D649CF10-89BD-498F-A12A-C86134F28526Q35785710-C25248D6-2303-4791-88EB-DA802E66F5F2Q35826503-113A9906-6B68-4AB0-82DD-BE1310874B19Q36106087-B887865A-03C7-4536-8FB1-58C9EFF1A678Q36230602-8029CB8D-B338-4C10-A01B-5BB2DE9BE25FQ36296828-F9756CBE-97DD-45B4-B814-27CEC05223B6Q36664108-465E2DEE-3321-45E9-A56F-14D2051CFFDBQ37093041-306A2999-35FD-4A41-ADE0-6F4A5FFBD3A9Q37254082-E6AF6541-F447-4992-A9EB-4E6E672CB61DQ37565645-40B7A77B-A79F-4E90-BC08-42289C80881CQ38508027-2CB0747D-B779-41B4-AFEB-8CE87EF41416Q42669105-DED49D3F-0B01-436E-8650-0A684E96130CQ46121546-6F1C80C7-1876-417C-AD28-F046903F51EAQ53261275-90AFC410-1724-47AC-A24F-E2A220F72228Q53829468-DB2F79FE-D096-40FE-BF3E-1702D8F4C28E
P2860
Research issues affecting preoperative systemic therapy for operable breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Research issues affecting preoperative systemic therapy for operable breast cancer.
@en
Research issues affecting preoperative systemic therapy for operable breast cancer.
@nl
type
label
Research issues affecting preoperative systemic therapy for operable breast cancer.
@en
Research issues affecting preoperative systemic therapy for operable breast cancer.
@nl
prefLabel
Research issues affecting preoperative systemic therapy for operable breast cancer.
@en
Research issues affecting preoperative systemic therapy for operable breast cancer.
@nl
P2093
P356
P1476
Research issues affecting preoperative systemic therapy for operable breast cancer
@en
P2093
David Mankoff
Donald Berry
JoAnne Zujewski
Judy E Garber
Lajos Pusztai
Lisa A Carey
Mary Lou Smith
Matthew Ellis
Mitchell Dowsett
Soonmyung Paik
P304
P356
10.1200/JCO.2007.15.2983
P407
P577
2008-02-01T00:00:00Z